1. Home
  2. RDI vs BOLD Comparison

RDI vs BOLD Comparison

Compare RDI & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reading International Inc

RDI

Reading International Inc

SELL

Current Price

$1.82

Market Cap

49.0M

ML Signal

SELL

Logo Boundless Bio Inc.

BOLD

Boundless Bio Inc.

N/A

Current Price

$2.44

Market Cap

54.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
RDI
BOLD
Founded
1937
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Movies/Entertainment
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
49.0M
54.5M
IPO Year
1994
2024

Fundamental Metrics

Financial Performance
Metric
RDI
BOLD
Price
$1.82
$2.44
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
27.0K
★ 86.2K
Earning Date
11-16-2026
11-10-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 60.76
32.47
EPS
★ N/A
N/A
Revenue
★ $202,988,000.00
N/A
Revenue This Year
$15.10
N/A
Revenue Next Year
$4.04
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.94
$0.96
52 Week High
$2.41
$3.16

Technical Indicators

Market Signals
Indicator
RDI
BOLD
Relative Strength Index (RSI) 53.66 42.40
Support Level $1.64 $2.32
Resistance Level $2.13 $2.65
Average True Range (ATR) 0.12 0.10
MACD 0.03 0.01
Stochastic Oscillator 65.85 9.52

Price Performance

Historical Comparison
RDI
BOLD

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

About BOLD Boundless Bio Inc.

Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Share on Social Networks: